Open AccessDevelopment and Validation of a New Risk Score for Infection with Coronavirus (Ri.S.I.Co) Obtained from Treating Coronavirus Disease (COVID-19) Patients on the Field
Author(s) -
Paola Fugazzola,
Francesco Favi,
Matteo Tomasoni,
Claudia Zaghi,
Chiara Casadei,
Enrico Prosperi,
Giacomo Sermonesi,
Davide Corbella,
Federico Coccolini,
Beniamino Praticò,
Vanni Agnoletti,
Luca Ansaloni
Publication year - 2020
Publication title -
iranian red crescent medical journal
Language(s) - English
Resource type - Journals
eISSN - 2074-1812
pISSN - 2074-1804
DOI - 10.5812/ircmj.106473
Subject(s) - medicine , covid-19 , epidemiology , logistic regression , pandemic , coronavirus , prospective cohort study , radiological weapon , emergency medicine , disease , surgery , infectious disease (medical specialty)
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has necessitated the alteration of the organization of entire hospitals to try to prevent them from becoming epidemiological clusters. The adopted diagnostic tools lack sensitivity or specificity. Objectives: The aim of the study was to create an easy-to-get risk score (Ri.S.I.Co., risk score for infection with the new coronavirus) developed on the field to stratify patients admitted to hospitals according to their risk of COVID-19 infection. Methods: In this prospective study, we included all patients who were consecutively admitted to the suspected COVID-19 department of the Bufalini Hospital, Cesena (Italy). All clinical, radiological, and laboratory predictors were included in the multivariate logistic regression model to create a risk model. A simplified model was internally and externally validated, and two score thresholds for stratifying the probability of COVID-19 infection were introduced. Results: From 11th March to 5th April 2020, 200 patients were consecutively admitted. A Ri.S.I.Co lower than 2 showed a higher sensitivity than SARS-Cov-2 nucleic acid detection (96.2% vs. 65.4%; P < 0.001). The presence of ground-glass pattern on the lung-CT scan had a lower sensitivity than a Ri.S.I.Co lower than 2 (88.5% vs. 96.2%; P < 0.001) and a lower specificity than a Ri.S.I.Co higher than 6 (75.0% vs. 96.9%; P < 0.001). Conclusions: We believe that the Ri.S.I.Co could allow to stratify admitted patients according to their risk, preventing hospitals from becoming the main COVID-19 carriers themselves. Furthermore, it could guide clinicians in starting therapies early in severe-onset cases with a high probability of COVID-19, before molecular SARS-CoV-2 infection is confirmed.